

1A-672-T025

Monoclonal Antibody to CD107b Allophycocyanin (APC) conjugated (25 tests)

Clone: **H4B4**

Isotype: Mouse IqG1

Specificity: The mouse monoclonal antibody H4B4 recognizes CD107b / LAMP-2, an

extensively glycosylated 100-120 kDa widely expressed lysosome-associated

protein.

HLDA V.; WS Code P007

Regulatory Status: RUO

Human PBMC Immunogen:

Species Reactivity: Human

Negative Species: Mouse. Rat

The purified antibody is conjugated with cross-linked Allophycocyanin (APC) under **Preparation:**

optimum conditions. The conjugate is purified by size-exclusion chromatography

and adjusted for direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 0.02% sodium azide.

Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not Storage / Stability:

use after expiration date stamped on vial label.

The reagent is designed for Flow Cytometry analysis of human blood cells using 10 μ l reagent / 100 μ l of whole blood or 10 6 cells in a suspension. Usage:

The content of a vial (0.25 ml) is sufficient for 25 tests.

Expiration: See vial label

Lot Number: See vial label

CD107b (lysosome-associated membrane protein-2, LAMP-2), together with **Background:**

CD107a / LAMP-1, is a major constituent of lysosomal membrane. The LAMP proteins are involved in lysosome biogenesis and are required for fusion of lysosomes with phagosomes, especially CD107b is important regulator in successful phagosomal maturation. CD107b deficiency causes an accumulation of autophagosomes in many tissues leading to cardiomyopathy and myopathy (Danons disease). Immature CD107b is an approximately 45 kDa protein, but after

extensive glycosylation the mature glycoprotein has about 100-120 kDa.



PRODUCT DATA SHEET

References:

*Apte SH, Baz A, Groves P, Kelso A, Kienzle N: Interferon-gamma and interleukin-4 reciprocally regulate CD8 expression in CD8+ T cells. Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17475-80.

*Palmer DR, Fernandez S, Bisbing J, Peachman KK, Rao M, Barvir D, Gunther V, Burgess T, Kohno Y, Padmanabhan R, Sun W: Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol. 2007 Jan;88(Pt 1):148-56.

*Denzer K, van Eijk M, Kleijmeer MJ, Jakobson E, de Groot C, Geuze HJ: Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J Immunol. 2000 Aug 1;165(3):1259-65.

*Thedrez A, Harly C, Morice A, Salot S, Bonneville M, Scotet E: IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy. J Immunol. 2009 Mar 15;182(6):3423-31.

*Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR: Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol. 2007 Aug;81(16):8468-76.

*Guia S, Cognet C, de Beaucoudrey L, Tessmer MS, Jouanguy E, Berger C, Filipe-Santos O, Feinberg J, Camcioglu Y, Levy J, Al Jumaah S, Al-Hajjar S, Stephan JL, Fieschi C, Abel L, Brossay L, Casanova JL, Vivier E: A role for interleukin-12/23 in the maturation of human natural killer and CD56+ T cells in vivo. Blood. 2008 May 15;111(10):5008-16.

*Meade JL, Wilson EB, Holmes TD, de Wynter EA, Brett P, Straszynski L, Ballard PA, Trapani JA, McDermott MF, Cook GP: Proteolytic activation of the cytotoxic phenotype during human NK cell development. J Immunol. 2009 Jul 15;183(2):803-13.

*Borgne-Sanchez A, Dupont S, Langonné A, Baux L, Lecoeur H, Chauvier D, Lassalle M, Déas O, Brière JJ, Brabant M, Roux P, Péchoux C, Briand JP, Hoebeke J, Deniaud A, Brenner C, Rustin P, Edelman L, Rebouillat D, Jacotot E: Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of alphaVbeta3-expressing endothelial cells. Cell Death Differ. 2007 Mar;14(3):422-35.

*And many other.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.